<DOC>
	<DOCNO>NCT02284048</DOCNO>
	<brief_summary>This study undertaken determine ticagrelor augment adenosine-induced coronary flow reserve ( CFR ) , ameliorate clinical symptomatology exercise tolerance patient MVA</brief_summary>
	<brief_title>Effect Ticagrelor Adenosine-Induced Coronary Flow Reserve Patients With Microvascular Angina</brief_title>
	<detailed_description>Considering reduce CFR increase platelet aggregability patient MVA , together augmented effect adenosine-mediated coronary blood flow potent antiplatelet effect ticagrelor , speculate ticagrelor promisingly ameliorate coronary microvascular function patient MVA .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>For inclusion study subject fulfill follow criterion : 1 . Provision inform consent prior study specific procedures 2 . Female male age 1880 year 3 . A diagnosis stable primary MVA base presence history typical effort angina , exerciseinduced STsegment depression &gt; 1 mm , normal nearnormal ( coronary artery stenosis &lt; 50 % ) coronary angiography , absence vasospastic angina coronary flow reserve ( CFR ) &lt; 2.5 leave anterior descend coronary artery assess coronary blood flow ( CBF ) response adenosine transthoracic Doppler echocardiography suboptimal control symptoms conventional antiischemic therapy , indicate occurrence &gt; 1 episode per week angina ubjects enter study follow exclusion criterion fulfil : 1. concomitance cardiac condition significant （ &gt; 50 % ）coronary plaque disease coronary artery spasm angiography evidence vasospastic angina valvular structural heart disease uncontrolled hypertension abnormal echocardiographic examination include leave ventricular hypertrophy 2. previous consumption ticagrelor 3. apparent contraindication ticagrelor administration . History Intracranial Hemorrhage Active Bleeding Severe Hepatic Impairment : AST ALT great 3 time upper limit . Bilirubin great upper limit . hypersensitivity ( e.g . angioedema ) ticagrelor component product severe COPD asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Ticagrelor</keyword>
	<keyword>Coronary Flow Reserve</keyword>
</DOC>